Status:
COMPLETED
Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Paget's Disease of the Bone
Hypocalcemia
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
This study will evaluate the impact of investigator and patient education and educational materials to foster calcium and vitamin D supplementation to mitigate the potential for hypocalcemia post Recl...
Eligibility Criteria
Inclusion
- Written informed consent
- As per currently approved Reclast® Package Insert:
Exclusion
- \- As per currently approved Reclast® Package Insert:
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT00668200
Start Date
May 1 2008
End Date
November 1 2012
Last Update
March 6 2015
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Phoenix, Arizona, United States, 85012
2
Novartis Investigative Site
Tucson, Arizona, United States, 85723-0001
3
Novartis Investigative Site
Gainesville, Georgia, United States, 30501
4
Novartis Investigative Site
Detroit, Michigan, United States, 48236